Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 609549, 6 pages
http://dx.doi.org/10.1155/2015/609549
Clinical Study

Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma

Department of Urology, Yantai Yuhuangding Hospital, Medical College of Qingdao University, 20 Yuhuangding East Road, Yantai, Shandong 264000, China

Received 14 October 2014; Revised 30 January 2015; Accepted 26 February 2015

Academic Editor: Haifeng Yang

Copyright © 2015 Chun-hua Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Pantuck, A. Zisman, and A. S. Belldegrun, “The changing natural history of renal cell carcinoma,” Journal of Urology, vol. 166, no. 5, pp. 1611–1623, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Strumberg, H. Richly, R. A. Hilger et al., “Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 965–972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Choi, C. Charnsangavej, S. C. Faria et al., “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1753–1759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3312–3318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. W. Ye and H. L. Zhang, “Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma,” OncoTargets and Therapy, vol. 7, pp. 925–935, 2014. View at Google Scholar
  7. C. Amin, E. Wallen, R. S. Pruthi, B. F. Calvo, P. A. Godley, and W. K. Rathmell, “Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy,” Urology, vol. 72, no. 4, pp. 864–868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. di Silverio, A. Sciarra, U. Parente et al., “Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy,” Urologia Internationalis, vol. 80, no. 4, pp. 451–453, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. Canadian Kidney Cancer Forum, “Management of kidney cancer: Canadian Kidney Cancer Forum consensus statement,” Canadian Urological Association Journal, vol. 2, pp. 175–182, 2008. View at Google Scholar
  10. T. Kondo, Y. Hashimoto, H. Kobayashi et al., “Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects,” Japanese Journal of Clinical Oncology, vol. 40, no. 12, pp. 1173–1179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. P. Steinberg, A. Finelli, M. M. Desai et al., “Laparoscopic radical nephrectomy for large (greater than 7’cm, T2) renal tumors,” Journal of Urology, vol. 172, no. 6, pp. 2172–2176, 2004. View at Publisher · View at Google Scholar · View at Scopus